Jaypirca is a prescription medicine used to treat adults with:
- Mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment and who have already received at least 2 treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received at least 2 treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine and a B-cell lymphoma 2 (BCL-2) inhibitor medicine
Jaypirca was approved based on how many people responded to treatment. Studies are ongoing to confirm the benefit of Jaypirca for this use.
It is not known if Jaypirca is safe and effective in children.
Jaypirca is a different kind* of BTK inhibitor for the treatment of relapsed or refractory† MCL and previously treated CLL
*Jaypirca is the only FDA-approved noncovalent BTK inhibitor.
Jaypirca, a noncovalent BTK inhibitor, works differently than other BTK inhibitors you may have taken before.
For MCL, it was developed to work after you have taken a covalent BTK inhibitor. For CLL, it works after you have taken a covalent BTK inhibitor and a BCL-2 inhibitor. There are no completed studies comparing Jaypirca to other BTK inhibitors.
What would you like to learn more about?
How do I take my medication?
What side effects might I experience?
How can I save on Jaypirca?
What were the results of the Jaypirca trial?